CAR-T Cells for the Treatment of Central Nervous System Tumours: Known and Emerging Neurotoxicities
The advent of chimeric antigen receptor (CAR)-T cells has recently changed the prognosis of relapsing/refractory diffuse large B-cell lymphomas, showing response rates as high as 60 to 80%. Common toxicities reported in the pivotal clinical trials include the cytokine release syndrome (CRS) and the...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
MDPI AG
2024-11-01
|
| Rangatū: | Brain Sciences |
| Ngā marau: | |
| Urunga tuihono: | https://www.mdpi.com/2076-3425/14/12/1220 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|